Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · April 26, 2021

Clinical Significance of CDKN2A Homozygous Deletion in Combination With Methylated MGMT Status for IDH-Wildtype Glioblastoma

Cancer Medicine

 

Additional Info

Cancer Medicine
Clinical Significance of CDKN2A Homozygous Deletion in Combination With Methylated MGMT Status for IDH-Wildtype Glioblastoma
Cancer Med 2021 Apr 10;[EPub Ahead of Print], Y Funakoshi, N Hata, K Takigawa, H Arita, D Kuga, R Hatae, Y Sangatsuda, Y Fujioka, A Sako, T Umehara, T Yoshitake, O Togao, A Hiwatashi, K Yoshimoto, T Iwaki, M Mizoguchi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Brain Cancer Center of Excellence

Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.


Further Reading